Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ICCC - Immucell Corp.


IEX Last Trade
3.74
-0.070   -1.872%

Share volume: 39,701
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.81
-0.07
-1.84%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
5%
Profitability 0%
Dept financing 11%
Liquidity 38%
Performance 1%
Company vs Stock growth
vs
Performance
5 Days
1.63%
1 Month
-10.31%
3 Months
-14.22%
6 Months
-28.35%
1 Year
-17.80%
2 Year
-48.84%
Key data
Stock price
$3.74
P/E Ratio 
-7.23
DAY RANGE
N/A - N/A
EPS 
-$0.52
52 WEEK RANGE
$3.50 - $5.64
52 WEEK CHANGE
-$0.18
MARKET CAP 
29.296 M
YIELD 
N/A
SHARES OUTSTANDING 
7.833 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$73,706
AVERAGE 30 VOLUME 
$47,911
Company detail
CEO: Michael Brigham
Region: US
Website: http://www.immucell.com/
Employees: 43
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immucell corporation is a biotechnology company based out of portland maine. immucell's focus is to create scientifically-proven and practical products that result in a measurable economical impact on animal health and productivity in the dairy and beed industries.

Recent news